Enable Injections’ drug delivery patch
Enable Injections is developing a subcutaneous drug delivery platform with the enFuse, which works as an on-body patch.
enFuse enables patient-administered subcutaneous delivery of high-volume therapeutics outside of the hospital. The on-body drug delivery platform has a self-contained drug transfer system that is compatible with standard syringes and vial container formats.
The platform is designed for controlled subcutaneous administration of large volumes that range from 5ml to 50ml. The company says the device can give patients and caregivers a different delivery method for subcutaneous administration of parenteral therapies outside of the doctor’s office.
Cincinnati-based Enable in 2019 partnered with Sanofi (NYSE:SNY) to develop long-term manufacturing and supply arrangements using multiple molecule development programs provided by the pharmaceutical giant. The company also last fall completed a credit facility worth $25 million from Oxford Finance LLC, earmarking the funds for supporting the scaling of high-volume manufacturing and the achievement of major inflection points as it moves toward commercialization.
